Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841801 | 1.00 | USP2 (0.59) | USP2HTTP2RY10ALDH1A1CNR1 | |
| SCHEMBL4814012 | 1.00 | USP2 (0.59) | USP2HTTP2RY10ALDH1A1CNR1 | |
| SCHEMBL14841798 | 1.00 | USP2 (0.59) | USP2HTTP2RY10ALDH1A1CNR1 | |
| SCHEMBL14848905 | 1.00 | USP2 (0.59) | USP2HTTP2RY10ALDH1A1CNR1 | |
| SCHEMBL14848930 | 0.95 | USP2 (0.54) | USP2HTTP2RY10ALDH1A1CNR1 | |
| SCHEMBL2998602 | 0.95 | USP2 (0.65) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL2998598 | 0.95 | USP2 (0.65) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL15295092 | 0.95 | USP2 (0.65) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL20124691 | 0.95 | USP2 (0.65) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL17743867 | 0.92 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643916-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643916-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643916-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | US | disclosed |
| EP-2575767-B1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2575767-B1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9315437-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315437-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9062021-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140235872-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235872-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235872-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8748667-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748667-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748667-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130090372-A1 | Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-04-11 | — | — | US | disclosed |
| US-20130090372-A1 | Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-04-11 | — | — | US | disclosed |
| WO-2011153120-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, NPC1L1 | USP2 3666/4885HTT 4497/4885P2RY10 4468/4885 |
| US-20130090372-A1 | Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery | LDLR, APOB, NPC1L1 | USP2 3666/4885HTT 4497/4885P2RY10 4468/4885 |
| US-20140235872-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, NPC1L1 | USP2 3666/4885HTT 4497/4885P2RY10 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.